title: Importance of Central Retinal Sensitivity for Prediction of Visual Acuity after Intravitreal Bevacizumb in Eyes with Macular Edema Associated with Branch Retinal Vein Occlusion.
abstract: OBJECTIVE
  To determine whether the baseline retinal sensitivity can predict the best-corrected visual acuity (BCVA) at 1 month after intravitreal bevacizumab (IVB) in eyes with macular edema (ME) associated with a branch retinal vein occlusion (BRVO).
  
  
  METHODS
  We evaluated 16 eyes of 16 patients who had ME associated with a BRVO. The mean ± standard deviation age was 69.1 ± 8.9 years, and all had a single IVB injection. The BCVA, central macular thickness (CMT), integrity of the ellipsoid zone (EZ) of the photoreceptors, and retinal sensitivity were determined before (baseline) and at 1 day, 1 week, and 1 month following the IVB. The average threshold retinal sensitivity (AT) within the central 10° was determined by Macular Integrity Assessment. The correlations between the BCVA at 1 month and the CMT, integrity of the EZ, and AT at each visit were determined.
  
  
  RESULTS
  One month after IVB, the BCVA improved significantly from 0.56 ± 0.27 logMAR units to 0.32 ± 0.28 logMAR units, and the CMT from 611.4 ± 209.3 μm to 258.7 ± 64.0 μm (P <0.05). The AT improved significantly from 17.9 ± 5.3 dB to 21.2 ± 5.0 dB (P <0.05). At 1 day after the treatment, both the integrity of the EZ (r = 0.59) and the retinal sensitivity (r = 0.76) were moderately correlated with the BCVA at 1 month.
  
  
  CONCLUSIONS
  These results indicate that both the integrity of the EZ and the AT at 1 day after the IVB can predict the BCVA after treatment for ME associated with BRVO. There is a possibility that these parameters will predict the effectiveness of IVB for each case.
authors.affiliation: Department of Ophthalmology, Mie University Graduate School of Medicine, Tsu, Japan.
authors.forename: Masahiko
authors.initials: M
authors.lastname: Sugimoto
authors.affiliation: Department of Ophthalmology, Mie University Graduate School of Medicine, Tsu, Japan.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Ichio
authors.affiliation: Department of Ophthalmology, Mie University Graduate School of Medicine, Tsu, Japan.
authors.forename: Mineo
authors.initials: M
authors.lastname: Kondo
mesh_terms: D000368:Aged; D000068258:Bevacizumab / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D012160:Retina / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology*; D012170:Retinal Vein Occlusion / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D014792:Visual Acuity
chemical_list: D000068258:Bevacizumab